Michael Gleeson Net Worth

The estimated Net Worth of Michael Gleeson is at least $14.1 million dollars as of 14 April 2021. Mr. Gleeson owns over 27,667 units of GenMark Diagnostics Inc stock worth over $10,106,656 and over the last 12 years he sold GNMK stock worth over $2,838,607. In addition, he makes $1,126,170 as Senior Vice President et Corporate Accounts at GenMark Diagnostics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Gleeson GNMK stock SEC Form 4 insiders trading

Michael has made over 104 trades of the GenMark Diagnostics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 27,667 units of GNMK stock worth $326,471 on 14 April 2021.

The largest trade he's ever made was exercising 83,836 units of GenMark Diagnostics Inc stock on 21 January 2021 worth over $2,015,417. On average, Michael trades about 4,805 units every 26 days since 2013. As of 14 April 2021 he still owns at least 420,410 units of GenMark Diagnostics Inc stock.

You can see the complete history of Mr. Gleeson stock trades at the bottom of the page.

Michael Gleeson biography

Michael W. Gleeson serves as Senior Vice President, Corporate Accounts of the Company. Mr. Gleeson previously served as Senior Vice President, North American Commercial Operations from March 2014 to August 2018, and as Senior Vice President, Sales of the Company from March 2012 to March 2014. Prior to that, he held the position of Vice President, U.S. Sales from November 2010 to March 2012. From May 2010 to November 2010, he served as National Sales Director for the Company and in the same capacity for Osmetech Technology, Inc., a wholly-owned subsidiary of Osmetech plc, since November 2009. Mr. Gleeson has over 15 years of experience in Director and Senior Sales Executive roles with both public and privately held companies in the enterprise software and services sector. Before joining the Company, Mr. Gleeson served as Senior Account Executive with Sybase (an SAP company), an industry leader in delivering enterprise and mobile software to manage, analyze and mobilize information from February 2009 to November 2009 and as Director, Financial Services with GuardianEdge Technologies (acquired by Symantec) from February 2006 to November 2008. Mr. Gleeson also held positions with BEA Systems (acquired by Oracle) and Cap Gemini Ernst & Young where he had responsibility in global sales, ISV, OEM and channel sales. Mr. Gleeson holds a B.S. degree in Entrepreneurial Studies from Babson College in Massachusetts.

What is the salary of Michael Gleeson?

As the Senior Vice President et Corporate Accounts of GenMark Diagnostics Inc, the total compensation of Michael Gleeson at GenMark Diagnostics Inc is $1,126,170. There are 2 executives at GenMark Diagnostics Inc getting paid more, with Scott Mendel having the highest compensation of $1,749,300.

How old is Michael Gleeson?

Michael Gleeson is 45, he's been the Senior Vice President et Corporate Accounts of GenMark Diagnostics Inc since 2018. There are 7 older and 2 younger executives at GenMark Diagnostics Inc. The oldest executive at GenMark Diagnostics Inc is Daryl Faulkner, 71, who is the Independent Director.

Insiders trading at GenMark Diagnostics Inc

Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem et Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.

What does GenMark Diagnostics Inc do?

Complete history of Mr. Gleeson stock trades at GenMark Diagnostics Inc

GenMark Diagnostics Inc executives and stock owners

GenMark Diagnostics Inc executives and other stock owners filed with the SEC include:

• Scott Mendel,
  President, Chief Executive Officer, Director
• Johnny Ek,
  Chief Financial Officer
• Michael Gleeson,
  Senior Vice President, Corporate Accounts
• Eric Stier,
  Senior Vice President, General Counsel, Secretary
• James Fox,
  Non-Executive Independent Director
• Kevin O'Boyle,
  Independent Chairman of the Board
• Lisa Giles,
  Independent Director
• Daryl Faulkner,
  Independent Director
• Michael Kagnoff,
  Independent Director
• Tyler Jensen,
  Senior Vice President - Engineering and Product Technical Support
• Jon Faiz Kayyem,
  President & CEO
• Jennifer Anne Williams,
  SVP Global Operations
• Wade R. Stevenson,
  SVP, North America Sales
• Brian Andrew Mitchell,
  SVP, Operations
• Christine Shaw,
  VP, Assay Development
• John Frederick Ek,
  Chief Financial Officer
• Richard B Slansky,
  Chief Financial Officer
• Stephen T Worland,
  Director
• Jeffrey Alan Hawkins,
  SVP, Marketing & Bus Dev
• Ingo Chakravarty,
  SVP, International
• Christopher M Gleeson,
  Director
• James B. Mc Nally,
  SVP, Marketing and Bus. Dev.
• Jorge Garces,
  SVP, Research & Development
• Paul Ross,
  CFO & Secretary
• Pankaj Singhal,
  Sr. VP, Product Dev & Mftg
• Matthew Robert Cohen,
  SVP, Gen Counsel & Secretary
• John Bellano,
  SR. VP, Commercial Operations
• Steven J Kemper,
  CFO, Treasurer & Secretary
• Bradley Calvin,
  Senior VP, Global Marketing
• Scott Alexander O'brien,
  SVP, Global Mktg & Int'l Sales
• Hany Massarany,
  President and CEO
• Sarah Hollis Winkler,
  VP, Human Resources
• Alan Baer Maderazo,
  VP, Qual, Reg, & Clin Affairs
• Michael John Harkins,
  SVP, Sales
• Abdul Chohan,
  SVP Operations